PharmaEngine Announce Its Partner, Nanobiotix, Received CE Mark Approval of PEP503 (NBTXR3, Hensify) for the Treatment of Locally Advanced Soft Tissue Sarcoma 2019/04/7 Uncategorized
PharmaEngine Announces Positive Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma 2018/06/21 Uncategorized
PharmaEngine’s Partner, Nanobiotix, Presents First Promising Data from Phase I/II Liver Cancer Trial of PEP503 at ASCO GI 2018/01/23 Uncategorized
PharmaEngine Announces Initiation of Phase 1b/2 Trial of PEP503 (NBTXR3) in Head and Neck Cancer 2016/10/19 Uncategorized
